Abstract. Immunosuppression may contribute to cancer progression, in which regulatory T (T-reg) cells have been demonstrated to play important roles. We investigated whether anti-CD25 (α-CD25) monoclonal antibody (mAb) and anticytotoxic T lymphocyte-associated antigen-4 (α-CTLA-4) mAb could augment in vitro proliferation and cytotoxic activity against cancer cell lines of lymphokine-activated killer (LAK) cells. Human LAK cells with immobilized α-CD3 Ab plus IL-2 were significantly augmented, including LAK/α-CD25 (10 μg ml, p=0.045) and LAK/α-CTLA-4 (5 μg/ml, p=0.025; 10 μg/ml, p=0.019). LAK/α-CD25 and LAK/α-CTLA-4 showed significant cytotoxic activities against gastric cancer cell lines (p<0.05). The phenotype of LAK cells showed that α-CD25 and α-CTLA-4 mAb more selectively induced the phenotype of CD8 + cells. The secretion of IFN-γ increased significantly in LAK/α-CTLA-4 (p=0.032). α-CD25 mAb reduced intracellular CTLA-4 (p=0.0069), and α-CTLA-4 mAb reduced intracellular FOXP3 (p=0.049), respectively. These results suggest that LAK cells are highly augmented in the presence of α-CD25 mAb and α-CTLA-4 mAb through the possible mechanism of the suppression of T-reg.
Introduction
Adoptive immunotherapy using lymphokine-activated killer (LAK) cells for human cancer was first introduced in 1985 (1), and limited clinical efficacy was demonstrated against renal cell carcinoma and malignant melanoma. Following LAK therapy studies, tumor-infiltrating lymphocyte (TIL) (2), cytotoxic T lymphocytes (CTLs) sensitized with autologous tumor cells (3), peptide-pulsed dendritic cell (DC)-activated killer cells (4) , and tumor RNA-induced DC-activated killer cells (5) were introduced into clinics; however, the clinical results of these adoptive immunotherapy trials showed limited efficacy (6) . It has been shown that tumor cells acquire an escape mechanism, including the haplotype loss of HLA expression in many types of clinical tumors (7) , and disordered antigen processing (8) . CTLs therefore fail to recognize these tumor cells, resulting in treatment failure. In this aspect of antigen presentation and recognition, effector cells that are not restricted HLA expression, such as LAK cells (9) , NK cells (9, 10) , NKT cells (10) , and γδ T cells (11) , may have an advantage in treating clinical tumors.
Another mechanism, by which tumor cells escape from the immune system, is immunosuppression in the tumorbearing host. It is well understood that immunosuppression may contribute to cancer progression. Recent studies have demonstrated that regulatory T (T-reg) cells, which have the phenotype of CD4 + CD25 + cells, contribute to immune dysfunction in cancer patients, and a relative increase in Treg cells is related to tumor progression in patients with esophageal cancer, gastric cancer and non-small cell lung cancer (12) (13) (14) . Cell-surface molecules, such as CD25, and intracellular molecules, such as cytotoxic T lymphocyteassociated antigen-4 (CTLA-4), are representative markers on T-reg cells (15, 16) . T-reg cell attenuation therapy may lead to the establishment of a more effective immunotherapy protocol for cancer patients.
In this study, we aimed to clarify the advantages of applying anti-CD25 (α-CD25) monoclonal antibody (mAb) and α-CTLA-4 mAb to down-modulate T-reg cells in the LAK cell induction system. Our results showed that proliferative responses, secretion of IFN-γ, and cytotoxic activity of LAK cells were augmented in the presence of α-CD25 mAb and, in particular, α-CTLA-4 mAb, indicating the possibility of novel effector cell generation for adoptive immunotherapy for cancer.
Materials and methods
Blood samples and cell isolation. Peripheral blood was collected from 7 healthy volunteers. Written informed consent under an Institutional Review Board-approved protocol was obtained from all subjects before enrollment in the study. Heparinized peripheral blood was obtained and then centrifuged over Lymphoprep (Nycomed Pharma, Norway) gradients for 15 min at 800 x g at room temperature. Peripheral blood mononuclear cells (PBMCs) were collected from the interface and washed three times.
Cell lines. and TMK-1 (17) are moderately and poorly differentiated human gastric adenocarcinoma cell lines, respectively. Cells were grown in RPMI-1640 containing 10% FCS (Gibco, Gaithersburg, MD, USA) in a humidified atmosphere containing 5% CO 2 at 37˚C.
Cell proliferation assay. PBMCs were labeled with 5 μM carboxyfluorescein diacetate succinimidyl ester (CFSE, Dojinkagaku, Kumamoto, Japan) for 8 min at 37˚C in a humidified 5% CO 2 incubator and washed extensively. PBMCs labeled with CFSE (1x10 5 /ml) were resuspended in RPMI-1640 (Gibco) medium containing 800 IU/ml IL-2 (TGP-3, Takeda Pharmaceutical Co., Ltd., Osaka, Japan) and 2% autologous serum, and stimulated to generate LAK cells in a round bottom 96-well tissue culture plate, coated with 1 μg/ml α-CD3 Ab (OKT-3, Kyowahakko, Tokyo, Japan) for more than 48 h (α-CD3/IL-2 system) and rinsed with RPMI-1640 medium more than three times. The cells were incubated at 37˚C in a humidified 5% CO 2 incubator for 7 days in the presence of either 5 μg/ml α-CD25 mAb (Ray Biotech, Norcross, GA) [LAK/α-CD25(5)], 10 μg/ml α-CD25 mAb [LAK/α-CD25(10)], 5 μg/ml F(ab')2 α-CTLA-4 Ab (Ancell, Bayport, MN) [LAK/α-CTLA-4(5)], 10 μg/ml F(ab')2 α-CTLA m-4 Ab [LAK/α-CTLA-4(10)] or 10 μg/ml control mouse Ig (Becton-Dickinson Biosciences, CA, USA) (LAK/Ig). Cells were subjected to flow cytometry, as described below, and proliferative activity was calculated from triplicate samples by the following formula ( Flow cytometry. After 7-day stimulation, CFSE-labeled or nonlabeled LAK cells were washed and resuspended in the medium, and subjected to flow cytometry to determine cell division. Three-color flow cytometry was also performed to determine T-cell phenotypes using α-CD3-Per-CP, α-CD4-FITC, α-CD4-PE, α-CD4-Per-CP, α-CD8-FITC, α-CD25-PE and α-CD62L-FITC Abs (Becton-Dickinson Biosciences). Flow cytometry was also performed to determine intracellular CTLA-4 and FOXP3. For intracellular staining of 7-day LAK cells with α-CTLA-4-PE Ab (Becton-Dickinson Biosciences), cells were fixed and permeabilized using a BD Cytofix/ Cytoperm (Becton-Dickinson Biosciences). Intracellular staining of 7-day LAK cells with α-FOXP3-FITC Ab was performed using an anti-human FOXP3 staining set (eBioscience, CA, USA) according to the manufacturer's directions. Flow cytometric analysis was performed on FACSCalibur (BectonDickinson, NJ, USA) and Cell Quest software (BectonDickinson). Lymphocytes were gated on CD3 + cells or using light scatter. The relative number of lymphocyte populations was expressed as a percentage (%) of the total number of lymphocytes.
Cytokine assay. Supernatants from the above cultures were harvested and frozen (-20˚C) until further use. Cytokine production of IFN-γ, TNF-α, IL-2, IL-4, IL-6 and IL-10 was measured using a CBA (Cytometric Bead Array kit, BectonDickinson Biosciences) according to the manufacturer's instructions. The results are expressed as pg/ml.
Statistical methods. Statistical analyses were performed using the paired and unpaired t-test. Significant difference was determined as p<0.05. Results are expressed as the mean ± SD.
Results

α-CD25 mAb and α-CTLA-4 Ab augment proliferation of LAK cells.
The proliferative responses of LAK cells generated with α-CD3/IL-2 system were assessed in the presence of α-CD25 mAb or α-CTLA-4 mAb by using CFSE (Fig. 1A) . (Fig. 2) . MKN-28 cells and TMK-1 cells admixed with LAK, LAK/α-CD25(10) and LAK/Ig cells grew and formed innumerable colonies. In contrast, both cancer cells co-cultured with LAK/α-CTLA-4(10) cells could not form colonies ( Fig. 2A and B) . DIs of MKN-28 cancer cells admixed with LAK, LAK/α-CD25(10), LAK/α-CTLA-4(10) and LAK/Ig cells were 100%, 73.0±10.7% (p=0.049), 46.1±1.5%, (p=0.0003) and 75.6±15.6%, respectively (Fig. 2C) , and those of TMK-1 cancer cells were 100%, 94.2±10.9%, 53.6±7.0% (p=0.0075) and 97.4±11.3%, respectively (Fig. 2D) . A significant increase of cytotoxic activity was observed in LAK/α-CTLA-4(10) cells against both tumor cells and in LAK/α-CD25(10) cells against MKN-28 cells compared to LAK cells.
Phenotypes of LAK cells stimulated with α-CD25 mAb and α-CTLA-4
Ab. Flow cytometric analysis was performed to determine the phenotypes of LAK cells induced with α-CD25 mAb and α-CTLA-4 mAb (Fig. 3) . (Fig. 3A-D) .
We next analyzed CD25 + and CD62L + cells in LAK cells (Fig. 3E-H 
α-CD25 mAb and α-CTLA-4 Ab augment IFN-γ secretion of LAK cells. IFN-γ production of LAK cells was examined in
the presence of α-CD25 mAb or α-CTLA-4 Ab using CBA (Fig. 4) . The secretion of IFN-γ from LAK, LAK/α-CD25(5), LAK/α-CD25(10), LAK/α-CTLA-4(5), LAK/α-CTLA-4(10) and LAK/Ig cells was 4664±1062, 5454±1240, 5741±772, 5800±741, 5893±439 and 5171±1780 pg/ml, respectively. Significantly higher levels of IFN-γ production were observed in LAK/α-CTLA-4(10) cells compared to LAK cells (p=0.032). All other cytokine levels showed no significant change (data not shown) (n=3).
α-CD25 mAb reduced intracellular CTLA-4 and α-CTLA-4
Ab reduced intracellular FOXP3 in 7-day LAK. Flow cytometric analysis was performed to determine the intracellular CTLA-4 and FOXP3 expression of 7-day LAK cells ( (p=0.0069) (Fig. 5A) , and intracellular FOXP3 + cells were significantly reduced in LAK/α-CTLA-4(10) cells (p=0.049) compared to LAK/Ig cells (Fig. 5B) .
Discussion
After the discovery of T-reg cells (15) , increasing attention has focussed on T-reg cell down-modulation combination in cancer immunotherapy. Dudley et al reported that adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy can mediate significant tumor regression in patients with metastatic melanoma (19) . In that study, the average CD4 + cell counts fell and did not recover for almost 6 months, whereas the average CD8 + cell counts transiently rose in lymphodepleting chemotherapy, suggesting the possible attenuation of T-reg cells by non-myeloablative lymphodepleting chemotherapy (19) . Several molecules, including CD25 (15), CTLA-4 (16), GITR (20) and FOXP3 (21) can be a target of T-reg cell depletion or functional inactivation. Clinical studies of tumor-specific peptide vaccination therapy combined with fully humanized α-CTLA-4 Ab have been reported and showed both cancer regression and severe autoimmunity (22) . Administration of diphtheria toxinconjugated recombinant IL-2, which selectively eliminates CD25-expressing T-reg cells, in tumor RNA-transfected DC vaccination therapy, showed improved tumor-specific T cell responses (23) . In this study, we investigated ex vivo stimulation of PBMCs with α-CD3/IL-2 culture system in the presence of α-CD25 mAb and α-CTLA-4 mAb, and demonstrated enhanced cell proliferation and cyto-toxic activity against tumor cells. Although CD25 and CTLA-4 are not specific markers expressed on T-reg cells as they can be also expressed on activated T cells, such as CTLs, the expression of CD25 and CTLA-4 molecules on T-reg cells is relatively and constitutively high (24) (22) have reported that effector cells induced in vivo with tumor-specific peptide vaccine in combination with α-CTLA-4 mAb recognize tumor antigens as well as self antigens, resulting in severe autoimmune diseases. Although we did not use antigen-presenting cells and antigens to generate LAK cells in vitro, our LAK cells may be reactive with self antigens, but this remains to be elucidated. Regarding the tumor escape mechanism, AIT using HLA-non-restricted effector cells may be indistinguishable in advances in tumor response when orchestrated with HLA-restricted approaches. Clinical trials of AIT using LAK cells are now in progress for the possible treatment of patients with metastatic cancer.
